Section of Geriatric Cardiology and Medicine, Department of Cardiovascular Medicine, University of Florence and Careggi Teaching Hospital, Florence, Italy.
Diabetes Care. 2011 Jan;34(1):129-31. doi: 10.2337/dc10-1287. Epub 2010 Oct 27.
Metformin is associated with reduced cancer-related morbidity and mortality. The aim of this study was to assess the effect of metformin on cancer incidence in a consecutive series of insulin-treated patients.
A nested case-control study was performed in a cohort of 1,340 patients by sampling, for each case subject, age-, sex-, and BMI-matched control subjects from the same cohort.
During a median follow-up of 75.9 months, 112 case patients who developed incident cancer and were compared with 370 control subjects. A significantly lower proportion of case subjects were exposed to metformin and sulfonylureas. After adjustment for comorbidity, glargine, and total insulin doses, exposure to metformin, but not to sulfonylureas, was associated with reduced incidence of cancer (odds ratio 0.46 [95% CI 0.25-0.85], P = 0.014 and 0.75 [0.39-1.45], P = 0.40, respectively).
The reduction of cancer risk could be a further relevant reason for maintaining use of metformin in insulin-treated patients.
二甲双胍与降低癌症相关发病率和死亡率有关。本研究旨在评估二甲双胍在一系列连续接受胰岛素治疗的患者中对癌症发病率的影响。
通过抽样，在 1340 名患者队列中进行了一项嵌套病例对照研究，为每个病例患者从同一队列中匹配年龄、性别和 BMI 相匹配的对照患者。
在中位随访 75.9 个月期间，112 名发生癌症的病例患者与 370 名对照患者进行了比较。接受二甲双胍和磺酰脲类药物治疗的病例患者比例明显较低。在调整合并症、甘精胰岛素和总胰岛素剂量后，与磺酰脲类药物相比，二甲双胍的暴露与癌症发病率降低相关（比值比 0.46 [95%CI 0.25-0.85]，P = 0.014 和 0.75 [0.39-1.45]，P = 0.40）。
降低癌症风险可能是维持接受胰岛素治疗的患者使用二甲双胍的另一个相关原因。
